PIM KINASE INHIBITOR LGH447
AML and High Risk MDS
Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the AML and High Risk MDS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Midostaurin Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
PIM KINASE INHIBITOR LGH447 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →